Abstract: The present invention relates to the use of atomic layer deposition (ALD) techniques to enhance the acid catalytic activity of nanoporous materials.

Abstract: A process for preparing a 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size in the range of 4 to 30 nm comprising the steps of: preparing an aqueous solution comprising an alkali silicate solution; preparing an aqueous solution comprising a poly(alkylene oxide) triblock copolymer and a buffer with a pH greater than 2 and less than 8, adding said aqueous alkali silicate solution to said aqueous solution giving a pH greater than 2 and less than 8 and allowing a reaction between the components to take place at a temperature in the range of 10 to 100° C., and filtering off, drying and calcinating the reaction product to produce said 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size.

Abstract: The invention describes a catalyst comprising at least one hydrodehydrogenating metal selected from the group formed by metals from group VIB and metals from group VIII and a support comprising at least one silica-alumina, and at least one COK-7 zeolite alone, or mixed with at least one ZBM-30 zeolite, as well as a process for hydrocracking hydrocarbon feeds employing said catalyst.

Abstract: An extravascular system includes a catheter assembly, a needle assembly, and a hemostatic adapter. The catheter assembly defines a lumen extending from a distal end thereof to a catheter hub at a proximal end thereof. The needle assembly includes a needle hub disposed at a proximal end of a needle disposed within the lumen defined by the catheter assembly. The hemostatic adapter defines a passage and is adapted to be operatively associated with the needle assembly and the catheter assembly. The hemostatic adapter-further includes at least one liquid-reactive material adapted to at least substantially seal the passage. The liquid-reactive material is selected and configured to morph upon contact with liquids to provide a mechanical barrier to prevent blood flow. A fluid may be injected into the lumen and/or passage by way of an optional port to provide a fluidic barrier in addition to the mechanical barrier.

Abstract: The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device, provided with at least one coating containing a therapeutic agent comprised in a matrix which sticks to the intraluminal device, characterised in that said matrix is formed by a biocompatible oil or fat, which oil or fat is a chemically hardened oil or fat.

Abstract: A tip shield of a catheter assembly has a resilient clip compartment, which may become blood-filled during use of the catheter assembly. The resilient clip inside the compartment is released upon withdrawal of the needle of the catheter assembly to disengage the catheter hub from the tip shield. The resilient clip also prevents re-exposure of the needle after being withdrawn into the tip shield. The blood-filled compartment may potentially leak or splash through an opening from the compartment when the resilient clip is released. A covering blocks the opening from the tip shield to minimize the risk of blood exposure. In addition, the covering minimizes the risk of premature release of the resilient clip and re-exposure of the needle.

Abstract: The present invention provides a new composite material comprising a polymer matrix comprising dispersed molecular sieve porous particles of which at least part are hollow particles, meaning that the particles comprise a shell enclosing cavities, of which the volume is at least two times larger than the average volume of the pores comprised in the shell of such particle. The invention further relates to membranes comprising such materials as well as the use of such membranes.

Abstract: The present invention provides zeolites and zeolite-like material having an enhanced microporosity. It was found that such zeolites can be obtained using a zeolite synthesis method comprising the preparation of a gel or solution for the synthesis of a zeolite, said gel or solution comprising appropriate amounts of (i) a conventional monomeric or polymeric silica source and (ii) a molecular template as a microstructuring agent, characterized in that said gel or solution further comprises an organosilane compound having limited self-assembling capacity.

Abstract: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.

Abstract: A silicate-based microporous ceramic molecular sieve membrane zeolite-like properties with an ordered stack of nanometre-sized slab-shaped building blocks having zeolite framework. A method for producing a membrane does not involve a hydrothermal treatment step, hence avoiding the formation of zeolite crystals.

Abstract: A method is provided for making pure-silica-zeolite films useful as low-k material, specifically, more hydrophobic, homogeneous and with absence of cracks. The method utilizes a UV cure; preferably the UV cure is performed at temperatures at higher than the deposition temperature. The UV-assisted cure removes the organic template promoting organic functionalization and silanol condensation, making the silica-zeolite films more hydrophobic. Moreover, the zeolite material is also mechanically stronger and crack-free. The method can be used to prepare pure-silica-zeolite films more suitable as low-k materials in semiconductor processing.

Abstract: The invention relates to a method and a system for the emulsification of a pre-mix of two or more immiscible liquids by flowing or circulating one or more times said pre-mix through one or more magnetic fields.

Abstract: The invention concerns a solid crystalline designated COK-7, which has a particular X ray diffraction diagram. Said solid has a chemical composition, expressed on an anhydrous base in terms of moles of oxides by the formula XO2: mYO2, X representing one or more tetravalent element(s), Y representing at least one trivalent element. The invention also concerns a process for preparing said solid and the use of said solid in hydrocarbon transformation.

Abstract: The invention concerns a process for the synthesis of solid zeolitic ZBM-30, comprising: i) a mixing step, during which a mixture comprising at least one source of a tetravalent metal, at least one source of a trivalent metal, water and at least two amine compounds is prepared, resulting in the production of a gel; and ii) a crystallization step, during which said gel is maintained under conditions allowing the formation of a crystalline solid. The invention also concerns the zeolite ZBM-30 obtained by said process.

Abstract: A catalyst comprising at least one zeolite (molecular sieve) chosen from the group formed by the TON structure type zeolites (Theta-1, ZSM-22, ISI-1, NU-10 and KZ-2) and at least one zeolite chosen from the group formed by the zeolites (ZSM-48, EU-2, EU-11 and ZBM-30), at least one porous mineral matrix, at least one hydro-dehydrogenating element, preferably chosen from the elements of Group VIB and Group VIII of the periodic table, is used for the conversion of hydrocarbons, in particular for the reduction of the pour point of charges containing long (more than 10 carbon atoms) linear and/or slightly branched paraffins, in particular in order to convert, with a good yield, charges having high pour points to at least one cut having a low pour point and a high viscosity index for oil bases.

Abstract: An apparatus for preventing blood exposure or contamination upon withdrawal of a hypodermic needle is provided. The apparatus may include a needle having a tip and a shield configured to at least partially entrap the needle tip upon withdrawal of the needle. The apparatus may further include a blood stabilizing material disposed such that upon withdrawal of the needle the blood stabilizing material is disposed in operative association with the needle tip such that blood carried by the needle is prevented from escaping the apparatus. In some exemplary implementations, the blood stabilizing material may be disposed on one or more surfaces of the shield. The shield of the hypodermic needle may include protective device and/or a housing for shielding the needle tip upon withdrawal. The housing may be adapted to at least partially cover the needle tip upon withdrawal of the needle.

Abstract: An extravascular system includes a catheter assembly, a needle assembly, and a hemostatic adapter. The catheter assembly defines a lumen extending from an opening at a distal end thereof to a catheter hub at a proximal end thereof. The needle assembly includes a needle hub disposed at a proximal end of a needle disposed within the lumen defined by the catheter assembly. The needle has a needle tip extending from the opening of the catheter assembly. The hemostatic adapter defines a passage and is adapted to be operatively associated with the needle assembly and the catheter assembly. The hemostatic adapter further includes at least one liquid-reactive material adapted to at least substantially seal the passage upon contact with one or more liquids. The liquid-reactive material is selected and configured to morph upon contact with liquids to provide a mechanical barrier to prevent blood flow.

Abstract: An extravascular system for accessing the vasculature of a patient including a catheter having an interior surface, a needle disposed within the catheter, and/or a needle cap defining at least one capillary space and including a flexible seal surrounding the at least one capillary space. The flexible seal may engage the interior surface of the catheter. A method of controlling exposure to a liquid from an extravascular system including providing a wicking material positioned adjacent to a flow channel such that any fluid located external to the flow channel is retained by the wicking material. The wicking material may be incorporated into any extravascular system where exposure to liquids is undesirable.

Abstract: Method and apparatus for reducing the average size of metallic compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having metallic compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the metallic compound particles or agglomerates by at least 25%.

Abstract: A coated implantable medical device is described, wherein the coating comprises a coating matrix and particles of one or more molecular sieves, preferably zeolite of zeogrid particles, optionally loaded with one or more bioactive agents. The coating matrix itself can function as a second drug-carrying interface. The coating comprising the molecular sieve material has an excellent biocompatibility and allows suitable drug delivery into the body of an animal, preferably a mammal and most preferably a human.